Metabolic medicines

Bupropion

An antidepressant with separate smoking-cessation and combination weight-management evidence; these are different clinical questions.

Randomized smoking-cessation evidence; distinct combination indication; checked 2026-10-01

Also known as: Wellbutrin · Zyban

Bupropion molecular structure — Structure reference · C13H18ClNO

Practical use

Clinical purpose, evidence and review questions

Define the target: Write down whether the goal is mood, tobacco abstinence or weight management.
Check the full list: Include combination products, eating-disorder history, seizure history and alcohol or sedative changes.
Measure the intended outcome: Track the relevant symptom or smoking outcome alongside sleep, blood pressure and adverse effects.

Sustained-release smoking-cessation trial

US prescribing information; checked October 1, 2026

Additional product-specific source

Overview

Bupropion affects noradrenergic and dopaminergic signaling. US Wellbutrin XL is indicated for major depression and seasonal-affective-disorder prevention. Smoking-cessation evidence includes a sustained-release formulation. Contrave combines bupropion with naltrexone for weight management; its results are not bupropion-alone results.

Risks and limitations

Risks include seizures, increased blood pressure, insomnia, agitation and activation of mania. Eating-disorder and seizure histories, abrupt withdrawal from alcohol or sedatives, and interacting medicines matter. New suicidal thoughts or major behavioral changes require prompt help; a seizure is an emergency.

How to read this

A reduction in weight gained after quitting smoking is different from losing weight in an obesity trial. Always retain the indication and formulation when comparing outcomes.

Research explained

Sustained-release smoking-cessation trial

Who was studied

615 smokers without current depression randomized to placebo or three bupropion groups for seven weeks, with brief counseling and follow-up to one year. Abstinence was checked with expired carbon monoxide.

What was found

At one year, abstinence rates were 12.4% with placebo and 19.6%, 22.9% and 23.1% across the three active groups; only the latter two comparisons were statistically significant. Among continuously abstinent participants, weight gain was smaller in the highest studied group.

What it cannot establish

Most participants were smoking again at one year. A subgroup’s reduced weight gain does not demonstrate standalone obesity treatment or a guaranteed result after quitting.

Read the original study

Check for duplicate ingredients

Bupropion can appear under different brand names or inside a combination. Contrave labeling contraindicates concurrent use of other bupropion-containing products.

Supporting source

Separate treatment success from side effects

Improved mood, smoking abstinence and weight change need separate assessment. Insomnia or appetite change is not sufficient evidence that the intended condition is improving.

Supporting source